AbCellera, Gilead collaborate for new multi-year, multi-target antibody discovery EP News Bureau Apr 1, 2021 Expanded collaboration includes an eight-target discovery partnership leveraging AbCellera’s entire technology stack
AbCellera gets EUA from US FDA for its antibody Bamlanivimab, along with Etesevimab for COVID-19 EP News Bureau Feb 10, 2021 Lilly plans to manufacture more than 250,000 doses of the bamlanivimab and etesevimab therapy throughout Q1 2021, and up to a…
AbCellera antibody gets US FDA EUA as monotherapy for COVID-19 treatment EP News Bureau Nov 10, 2020 AbCellera’s partner, Eli Lilly and Company, will supply the US government with 300,000 doses of bamlanivimab for allocation to…
